Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes.

Abstract

Primary plasma cell leukaemia (PPCL) is a rare form of plasma cell neoplasm. Treatments of PPCL have been most disappointing. A patient with PPCL received high-dose melphalan plus total body irradiation and autologous bone marrow transplantation (ABMT). By using third-complementarity-determining region (CDRIII)-specific probes, minimal residual disease (MRD) was detected in remission marrow, collected 1 month before ABMT. MRD was no longer detected by CDRIII-specific probes 6, 19 and 26 months after transplantation. The patient remained in complete remission up to 59 months after ABMT.

• Authors: K H Yeh, M T Lin, J L Tang, C H Yang, W Tsay, Y C Chen
• Journal: British journal of haematology (Br J Haematol) Vol. 89 Issue 4 Pg. 914-6 (Apr 1995) ISSN: 0007-1048 [Print] England
• PMID: 7772534 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• DNA Probes

Topics

• Adult
• Base Sequence
• Bone Marrow Transplantation
• DNA Probes
• Disease-Free Survival
• Female
• Humans
• Leukemia, Plasma Cell (therapy)
• Molecular Sequence Data
• Neoplasm, Residual (diagnosis)
• Transplantation, Homologous